Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Merrimack Pharma

Sanofi reception

Sanofi fires off another lawsuit against a Lantus biosimilar

Alleges patent infringement by Merck & Co’s biosimilar version filed in the US last month

- PMLiVE

Lilly closes on first approval for sarcoma drug Lartruvo

Orphan drug improved patient survival time by almost 12 months in phase II trial

- PMLiVE

Combatting EU drug shortages

New guidelines to be issued after EMA report

- PMLiVE

Newron back on track for Xadago approval in US

Italian firm is not required to conduct additional trials for its Parkinson’s disease drug

- PMLiVE

Retrophin rockets away as rare disease trial hits targets

Sparsentan has potential to become a blockbuster FSG drug, according to analysts

- PMLiVE

Merck closes in on first-line NSCLC label for Keytruda in US

Accelerated FDA review could see PD-1 inhibitor approved by the end of the year

- PMLiVE

Allergan CEO takes issue with ‘predatory’ price increases

Saunders adds voice to drug pricing outcry saying perpetrators break “social contract”

- PMLiVE

Nestlé Health Science buys medical device firm

Acquisition of UK's Phagenesis expected to be completed by 2019

- PMLiVE

Clinton takes aim at pharma pricing once again

Pledges to establish new enforcement powers to address “unjustified price hikes”

Roche Basel Switzerland

Roche’s checkpoint inhibitor Tecentriq aces lung cancer trial

Second-line therapy showed overall survival benefit irrespective of PD-L1 status

Shire Basingstoke

Shire launches dry eye drug Xiidra in US

Sparks rivalry with Allergan’s blockbuster Restasis as first new dry eye treatment in 13 years

- PMLiVE

Takeda: No decision yet on shutdown of Cambridge, UK unit

Tells PMLiVE that consultation over proposed closure of R&D site still ongoing

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links